Universal-Beteiligungs- und Servicegesellschaft
MLYS icon

Universal-Beteiligungs- und Servicegesellschaft’s Mineralys Therapeutics MLYS Stock Holding History

Universal-Beteiligungs- und Servicegesellschaft’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,689
Closed -$533K – 2170
2026
Q1 		$533K Buy
19,689
+7,692
+64% +$226K ﹤0.01% 1697
2025
Q4 		$435K Buy
+11,997
New +$481K ﹤0.01% 1754

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft's MLYS Position: Q2 2026 in Review

Universal-Beteiligungs- und Servicegesellschaft sold out of Mineralys Therapeutics (MLYS) in Q2 2026, closing a stake of 19,689 shares — an estimated $533K sold.

Universal-Beteiligungs- und Servicegesellschaft first reported a position in MLYS in Q4 2025 and held it in 2 quarters. The position peaked at $533K in Q1 2026. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Universal-Beteiligungs- und Servicegesellschaft reported no remaining Mineralys Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Universal-Beteiligungs- und Servicegesellschaft sold 19,689 Mineralys Therapeutics shares in Q2 2026, an estimated $533K.
  • Universal-Beteiligungs- und Servicegesellschaft first reported a position in Mineralys Therapeutics in Q4 2025 and held it in 2 quarters.
  • Universal-Beteiligungs- und Servicegesellschaft's Mineralys Therapeutics position peaked at $533K in Q1 2026.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Universal-Beteiligungs- und Servicegesellschaft's 13F filing for Q2 2026, filed 6 Aug 2026.